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Resistance to thyroid hormone with a mutation of the 
thyroid b receptor gene in an eight-month-old infant 
— a case report
Zespół oporności na hormony tarczycy spowodowany mutacją w genie 
kodującym podjednostkę b receptora hormonów tarczycy u 8-miesięcznego 
niemowlęcia: opis przypadku
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Agnieszka Zachurzok
Department of Paediatrics and Paediatric Endocrinology, School of Medicine in Katowice, Katowice, Poland
Abstract 
Introduction: Resistance to thyroid hormone (RTHb) is a rare syndrome of impaired tissue responsiveness to thyroid hormones (THs). 
The disorder has an autosomal dominant or recessive pattern of inheritance. Most of the reported mutations have been detected in the 
thyroid hormone receptor b gene (THRB). 
Case report: Authors present an eight-month-old infant with poor linear growth, decreased body weight, tachycardia, positive family 
history, and neonatal features suggestive of RTHb. Both our patient and his mother had elevated free thyroxine, free triiodothyronine, 
and non-suppressed thyrotropin (TSH) concentration. The fluorescent sequencing analysis showed a heterozygous mutation c.728G>A in 
TRb gene. This pathogenic variant is known to be associated with THR.
Conclusions: The clinical presentation of RTHb is variable, ranging from isolated biochemical abnormalities to symptoms of thyrotoxicosis 
or hypothyroidism. The syndrome should be suspected in patients with increased serum TH level, accompanied by a normal or elevated 
TSH concentration. The affected patients require individualised management. (Endokrynol Pol 2019; 70 (1): 124–130)
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Streszczenie
Wstęp: Zespół oporności na hormony tarczycy to rzadka, uwarunkowana genetycznie choroba, spowodowana zmniejszoną wrażliwo-
ścią tkanek obwodowych i/lub komórek tyreotropowych przedniego płata przysadki na działanie hormonów tarczycy (HT). Najczęstszą 
przyczyną zespołu są punktowe mutacje w genie THR kodującym podjednostkę b receptora hormonów tarczycy. Dziedziczenie jest 
autosomalne dominujące lub autosomalne recesywne. 
Opis przypadku: W pracy przedstawiono opis przypadku 8-miesięcznego niemowlęcia ze słabym przyrostem masy i długości ciała, 
tachykardią oraz dodatnim wywiadem rodzinnym w kierunku zespołu oporności na hormony tarczycy. Zarówno u probanta, jak u jego 
matki stwierdzano podwyższone stężenie wolnej tyroksyny i trójjodotyroniny, przy braku supresji sekrecji tyreotropiny (TSH). Przepro-
wadzono sekwencjonowanie genu TRb, stwierdzając heterozygotyczną mutację c.728G>A, o której wiadomo, że może być przyczyną 
oporności na hormony tarczycy.
Wnioski: Obraz kliniczny zespołu oporności na hormony tarczycy jest zmienny; większość pacjentów znajduje się w stanie eutyreozy, 
u niektórych obok objawów niedoczynności występują objawy nadczynności gruczołu tarczowego. Zespół należy podejrzewać u pacjen-
tów z brakiem supresji wydzielania TSH mimo podwyższonych stężeń hormonów tarczycy. Leczenie powinno być zindywidualizowane. 
(Endokrynol Pol 2019; 70 (1): 124–130)
Słowa kluczowe: zespół oporności na hormony tarczycy; receptor b dla hormonów tarczycy; niemowlę
Introduction 
Resistance to thyroid hormone (RTHb) is a rare syn-
drome of impaired tissue responsiveness to thyroid 
hormones (THs) [1, 2]. The incidence of RTHb is ap-
proximately 1:40,000–1:50,000 per live births, and the 
inheritance is autosomal dominant or recessive [1, 
3]. Nonetheless, approximately 15% of the cases are 
sporadic [3]. The thyroid hormone receptor (TR) had 
two subtypes (TRa, TRb), which are encoded by genes 
(THRA, THRB) located on chromosomes 17 and 3, 
and with three main isoforms (TRa, TRb1, TRb2) with 
organ-specific distribution [4]. 
The most common causes of the syndrome are 
genetic mutations in THRB gene [2, 5]. However, in 
some cases no mutations have been detected [6]. Recent 
studies have demonstrated THRA mutations, produc-
ing defective TRa, as another cause of RTH (termed 
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RTHb) [7]. The RTHb used to be classified into gener-
alised (GRTH) or pituitary (PRTH) [8]. The clinical mani-
festation is heterogeneous, even between members of 
the same family harbouring the same mutation. The 
syndrome can present with variable symptoms, ranging 
from isolated biochemical abnormalities to symptoms 
of thyrotoxicosis or hypothyroidism. The biochemical 
hallmark of RTHb is elevated serum TH, along with 
non-suppressed level of thyrotropin (TSH). The treat-
ment decision should be individualised, depending on 
the clinical presentation in each patient [2, 9, 10].
Case report
An eight-month-old boy was referred to the Depart-
ment of Paediatrics and Paediatric Endocrinology due to 
abnormal thyroid function test: elevated free thyroxine 
(FT4) and free triiodothyronine (FT3) concentration, 
along with TSH level within the normal range, accom-
panied by poor weight gain and tachycardia. 
He was born as the first child of nonconsanguine-
ous parents, by Caesarean section at gestational week 
36, due to pregnancy complicated by oligohydramnios, 
breech presentation, and premature obsolescence of 
placenta. Additionally, during the third trimester of 
pregnancy growth retardation and acceleration and 
deceleration of foetal heart rate were observed. The 
birth weight was 2300 g (3rd–10th centile, SDS: –1.65) 
and length was 51 cm (75th–90th centile, SDS: +2.6). 
The birth head circumference was 32 cm (3rd–10th 
centile), and the size of the anterior fontanelle in the 
perinatal period was 1 × 1 cm. To evaluate the birth 
parameters the growth charts by Palczewska and 
Niedźwiecka for boys born between 32 and 37 week 
of gestation (Hbd) were used [11, 12]. The postnatal 
period was complicated by feeding difficulties, due 
to weak sucking reflex and retrognathia. Significant 
failure of thrive was noted, with weight remaining 
below the 3rd centile. Due to his positive family history 
and suggestive neonatal features of RTHb, THs were 
checked, revealing FT4 and FT3 levels exceeding the 
upper limit of normal range, accompanied by normal 
TSH concentration.
On admission to the hospital at age eight months, 
the patient’s length was 67 cm (25th centile) and his 
weight was 5.7 kg (< 3rd centile) [12]. Physical exami-
nation showed microcephaly (head circumference: 41 
cm, < 3rd centile), closed anterior fontanelle, facial dys-
morphia (almond-shaped, slanted eyes, flat philtrum), 
dry skin, very scarce subcutaneous fat tissue devel-
opment, and tachycardia (160 bpm) [12]. Laboratory 
findings included: FT3 13.11 pg/ml (reference range: 
2.15–5.83 pg/ml), FT4 4.00 ng/dL (reference range: 
0.65–2.30 ng/dL), TSH 5.390 µIU/mL (reference range: 
0.730–8.350 µIU/mL), antiTG < 20.0 IU/ml (reference 
range: 0.0–40.0IU/ml), and antiTPO < 10.0 IU/ml (refer-
ence range: 0.0–40.0 IU/ml), TRAb 1.29 IU/l (reference 
range: < 2 IU/l). To exclude a TSH-secreting pituitary 
adenoma a thyrotropin-releasing hormone (TRH) stim-
ulation test was performed, and it showed a robust TSH 
response (time 0’— 4.7 µIU/mL, 20’ — 59.67 µIU/mL, 
30’ — 57.36 µIU/mL, 60’ — 32.52 µIU/mL, 120’ — 23.43 
µIU/mL). The results of complete blood count, renal 
and liver function, blood glucose, and routine urinalysis 
were within normal ranges. The result of biochemical 
analyses performed at the Institute of Metabolic Science 
are included in Table I. 
Electrocardiography confirmed sinus tachycar-
dia. Bone age was delayed and assessed as neonatal 
(Fig. 1). Ultrasound of the thyroid gland revealed no 
thyroid enlargement and no increased vascular flow 
pattern on Colour Doppler examination; echogenicity 
Table I. The result of biochemical analyses performed at Institute of Metabolic Science; Addenbrooke’s Hospital; Cambridge 
Tabela I. Wyniki analiz biochemicznych przeprowadzonych w Instytucie Nauk Metabolicznych (Addenbrooke’s Hospital; 
Cambridge)
Proband Proband’s mother
TSH (Delfia) 2.75 [0.40–4.00 mU/L] 1.44 [0.40–4.00 mU/L]
Free T4 (Delfia) 37.3 [9.0–20.0 pmol/L] 30.0 [9.0–20.0 pmol/L]
Calculated free T4 45.0 29.0
Free T3 (Delfia) 10.9 [3.0–7.5 pmol/L] 10.1 [3.0–7.5 pmol/L]
Total T4 296.0 [69.0–141.0 nmol/L] 241.0 [69.0–141.0 nmol/L]
TBG 25.4 [14.0–31.0 ug/ml] 26.7 [14.0–31.0 ug/ml]
TSH (Siemens Centaur) 3.25 [0.35–5.50 mU/L] 1.59 [0.35–5.50 mU/L]
Free T4 (Siemens Centaur) 35.8 [10.0–19.8 pmol/L] 26.8 [10.0–19.8 pmol/L]
Free T3 (Siemens Centaur) 10.2 [4.3–7.6 pmol/L] 9.0 [3.5–6.5 pmol/L]
TSH — thyroid-stimulating hormone; T4 — thyroxine; T3 — triiodothyronine; TBG — thyroxine-binding protein
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was moderately decreased and heterogeneous. The 
psychomotor development was assessed as average 
for the child’s age.
The patient’s mother also presented abnormal 
thyroid function. She was born at 41 weeks of gesta-
tion with low birth weight (2270 g, < 3rd centile) and 
low length (50 cm, < 3rd centile) [13]. Her current 
weight and height were 50 kg (10th–25th centile, –1.4 
SDS) and 156 cm (3rd–10th centile, –1.67 SDS), and her 
BMI was 20.6 kg/m2. She had suffered from persistent 
tachycardia since childhood. Additionally, as a child 
she exhibited attention deficit, hyperirritability, and 
learning difficulties. The patient’s mother was misdi-
agnosed for several years. Finally, in adulthood, she 
was referred to the endocrinologist due to persistent 
elevation of serum level of FT3 and FT4 with normal 
TSH concentration. AntiTg, antiTPO, and TRAb 
autoantibodies were negative. Her thyroid function 
panels are reviewed and presented in Table II. Oral 
administration of metizol (thiamazole) did not lead 
to normalisation of THs or clinical improvement. 
Anti-thyroid drug therapy was continued during 
pregnancy. Additionally, she was also treated em-
pirically with a beta-blocker. Ultrasonography of her 
thyroid showed the gland to be of normal volume 
with a single nodule in the left lobe (colloid nodule 
diagnosed in fine needle biopsy). The pituitary MRI 
was normal, and no adenoma was found. After 
exclusion of the possibility of TSH-producing pitu-
itary adenoma, the diagnosis of RTHb was highly 
suspected. However, no genetic test was performed 
at this time. It is noteworthy that also the proband’s 
grandmother had a medical history of thyroidectomy 
due to goitre in the course of hyperthyroidism. The 
genetic tests were performed in the proband and his 
mother. Fluorescent sequencing analysis detected 
a heterozygous base change, c.728G>A, in exon 7 of 
THRB gene in the child as well as in his mother. This 
pathogenic variant is predicted to result in abnormal 
TRb protein (p.Arg243Gln) and has been previously 
associated with RTHb [14].
Normalisation of the patient’s heart rate and blood 
pressure were initially obtained by the administration 
of the b-blocker (propranolol, 2.5 mg twice a day). 
For the last two years the boy has remained under 
the care of an endocrine outpatient clinic. During 
this time his THs concentration stayed elevated with 
non-suppressed TSH level (Tab. III). Ultrasound of 
the thyroid gland showed a minor enlargement of 
the thyroid. The main clinical problem was persistent 
(mild) tachycardia (100–120 bpm on average), hyper-
activity, and failure to thrive. His current weight, at 
the age of three years and six months, is 9.9 kg (< 3rd 
centile, –4.07 SDS) and his height is 89.7 (< 3rd centile, 
–2.88 SDS) [13] (Fig. 2, 3). Additionally, the bone age, 
Figure 1. Radiograph of the left hand taken at the age of 8 months. 
Bone maturation was delayed and assessed as neonatal
Rycina 1. Badanie RTG lewej ręki przeprowadzone u probanda w 
wieku 8 miesięcy. Widoczne opóźnione dojrzewanie kości, oceniano 
je jako noworodkowe
Table II. Thyroid function panel of proband’s mother from 2012 to 2015
Table II. Wyniki badań czynności tarczycy matki probanda w latach 2012–2015
Reference 
value 05/2012 07/2013 01/2014 02/2014 06/2014 09/2014 10/2014 11/2014 12/2014 02/2015
TSH [mU/L] 0.270–4.200 2.200 2.620 1.730 1.540 1.340 1.680 2.88 2.01 1.730 2.240
FT4 [pmol/L] 12.00–22.00 41.33 30.98 40.36 35.48 36.19 36.29 32.56 28.57 23.33 22.98
FT3 [pmol/L] 3.10–6.80 10.88 9.82 10.62 8.87 7.62 10.4 12.78 10.86 9.24 9.16
Dose 
of tiamazol 
[mg/d]
– 10 – – – – – 5 2.5 2.5 
TSH — thyroid-stimulating hormone; FT4 — free thyroxine; FT3 — free triiodothyronine
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assessed according to the Greulich and Pyle method, 
was significantly delayed and asynchronous (wrist 
bone age and metacarpal bone age: three month, 
phalanges bone age: one year and six months – two 
years) (Fig. 4). Treatment with a b-blocker was stopped 
due to poor drug tolerability (anxiety, nightmares). No 
anti-thyroid drug treatment was introduced. Due to 
the relatively mild presentation of the disease, absence 
of severe tachycardia, stabilisation in growth, and 
normal development of the child, more aggressive 
treatment has not been needed so far.
Discussion
Resistance to thyroid hormone is a rare genetic disor-
der with an autosomal dominant or recessive model of 
inheritance, characterised by various clinical presenta-
tions even within the families with the same mutation 
[1, 2]. The first case of RTH syndrome was reported by 
Refetoff et al. in 1967.
The thyroid hormone receptor belongs to the 
nuclear receptor superfamily and has four functional 
domains: transcription activation domain, DNA-bind-
Table III. Thyroid function panel of proband from 2016 to 2017
Table II. Wyniki badań czynności tarczycy probanda w latach 2016–2017
Reference value 05/2016 01/2016 08/2017 09/2018
TSH [uIU/mL] 0.700–5.970 4.060 2.320 3.63 3.02
FT4 [ng/dL] 0.65–2.3 2.74 3.51 2.75 3.00
FT3 [pg/mL] 2.41–5.50 7.29 8.21 9.68
TSH — thyroid-stimulating hormone; FT4 — free thyroxine; FT3 — free triiodothyronine
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Figure 2. The growth curve of the proband according to the height 
growth chart by Palczewska and Niedźwiecka for boys born between 
32 and 37 Hbd
Rycina 2. Krzywa wzrostu probanda zgodnie z siatką centylową 
Palczewskiej i Niedźwieckiej dla chłopców urodzonych między 32. 
i 37. tygodniem ciąży
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Figure 3. The weight curve of the proband according to the weight 
growth chart by Palczewska and Niedźwiecka for boys born between 
32 and 37 Hbd
Figure 3. Krzywa masy ciała probanda zgodnie z siatką centylową 
Palczewskiej i Niedźwieckiej dla chłopców urodzonych między 32. 
i 37. tygodniem ciąży
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ing domain, hinge region, and ligand binding domain. 
Each of the thyroid hormone receptors (TRa, TRb) has 
two different isoforms. Only TRa1, TRb1, and TRb2 
are able to bind THs. The receptors have specific organ 
distribution. TRa1 is widely expressed, especially in 
cardiac and skeletal muscles, gastrointestinal tract, and 
central nervous system (CNS). TRb1 is mainly expressed 
in brain, liver, and kidney; TRb2 expression is primarily 
limited to the hypothalamus and pituitary [4]. TRa2 is 
also widely expressed but unable to bind hormones; its 
function is not fully understood.
Approximately 85% of individuals with RTHb have 
a THRB mutation [2, 5]. Approximately 170 different 
mutations of the THRB gene have been described. Most 
of the mutations are single-nucleotide substitutions [5, 
15]. The majority of them are located in three hotspot re-
gions between exon 7 and 10 [16]. Mutations may result 
in reduced or absent T3 binding to the mutant receptor; 
some mutant TRb have an abnormal interaction with 
coactivators and corepressors involved in mediating TH 
action via the receptor. Additionally, mutant receptors 
are characterised by dominant negative activity and are 
capable of interfering with the function of the wild-type 
receptor [16]. The mutation identified in our proband 
and his mother was first described by Onigata et al. 
in 1995. This single nucleotide substitution, guanine 
for adenine, was identified at the second position of 
243 codon located in the hinge domain between the 
ligand binding and DNA binding domains, resulting 
in the substitution of arginine with glutamine. This 
leads to reduced ligand affinity but also to inhibition of 
wild-type TRb action in a dominant negative manner. 
Reversal of the inhibition is possible with the higher T3 
concentration [14].
The clinical presentation of RTHb is variable, from 
completely asymptomatic to hyper- or hypothyroid 
signs and symptoms or a combination of them [9]. 
The variability seen in the clinical presentation could 
be explained by different tissue distribution of TR 
isoforms, individual tolerance to elevated THs levels, 
or varying mutant TR tissue expression [17]. The RTHβ 
syndrome has been classified into generalised (GRTH) 
or pituitary (PRTH) [2,8]. Approximately 80% of cases 
belong to GRTH type. The majority of patients with 
GRTH are clinically euthyroid. Patients with PRTH 
exhibit symptoms of tissue-specific mild to moderate 
hyperthyroidism. However, in some cases, differentiat-
ing selective PRTH from GRTH may be difficult. [2, 9].
Early goitre development is one of the most com-
mon clinical findings, and it is observed in 66–95% of 
RTHb patients. Enlargement of the thyroid is related 
to the continuously high level of TSH that stimulates 
the thyroid to overgrow. Some individuals present 
symptoms of TH insufficiency, such as growth retarda-
tion with delayed bone age, intellectual impairment, 
or hypercholesterolaemia. Recent studies showed that 
approximately 50% of patients have learning disabili-
ties, such as Attention Deficient Hyperactivity Disorder 
(ADHD) and lower intellectual quotients. However, 
mental retardation (IQ < 60) occurs exclusively in 3% 
of cases. Many individuals manifest signs of TH excess, 
such as sinus tachycardia (80–90%), advanced bone 
maturation, or hyperactivity. Some patients may also 
present combination of symptoms of TH deficiency 
and excess [9]. It has been observed that the symptoms 
become milder with age. Patients with homozygous 
mutations in THRB exhibit a more severe phenotype. 
Other common complaints include recurrent ear infec-
tion and sensorineural deafness. The individuals also 
present dysmorphic features such as bird-like facies 
with prominent nasal bridge, pigeon chest, or winged 
scapulae. This severe phenotype is probably due to the 
dominant negative effect of the mutant protein and the 
lack of functional TRb [18, 19]. In our patient a combi-
nation of hypo- and hyperthyroidism symptoms was 
observed. He is a carrier of heterozygous mutation in 
THRB, and some symptoms of TH excess are present 
(tachycardia, hyperactivity, poor weight gain); however, 
they are not severe. Moreover, some features suggesting 
hypothyroidism (delayed bone age) were also observed.
Figure 4. Radiograph of the left hand taken at the age of 3 years 
and 6 months. Bone maturation was delayed and asynchronous 
(wrist bone age and metacarpal bone age: 3 months, phalanges 
bone age: 1 year and 6 months – 2 years) 
Rycina 4. Badanie RTG lewej ręki przeprowadzone u probanda 
w wieku 3 lat i 6 miesięcy. Widoczne opóźnione i niesynchroniczne 
dojrzewanie kości (kość nadgarstka i kość śródręcza: wiek oceniono 
na 3 miesiące, paliczki palców: wiek oceniono na 1,5–2 lata)
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The syndrome should be suspected in patients with 
increased serum TH level accompanied by a normal or 
elevated TSH concentration. Due to lack of pathogno-
monic symptoms associated with RTHb, the diagnosis 
of this disorder should be confirmed by the clinical 
examination, laboratory findings, and gene mutation 
analysis. Because of variability of the clinical presen-
tation of RTHb syndrome, affected patients require 
individualised management. Avoidance of inappropri-
ate treatment is especially important when managing 
infants and children. 
At present, specific treatments for RTHb are not 
available. The majority of affected patients compensate 
for tissue resistance by increased endogenous supply 
of TH and do not require therapy [10]. The administra-
tion of TH is reserved for individuals with insufficient 
tissue hyposensitivity compensation, especially in cases 
of autoimmune thyroiditis coincidence. The aim of the 
therapy is to diminish symptoms of hypothyroidism 
and to reduce serum TSH concentration to a normal 
level. The optimal dose of exogenous TH is variable 
and highly individual. Patients with RTHb with evi-
dence of hypothyroidism (elevated TSH, symptoms of 
hypothyroidism, positive anti-TPO antibodies) require 
the administration of supraphysiological, incremental 
doses of levothyroxine (LT4). This therapy requires care-
ful monitoring of markers of TH action, such as SHBG, 
cholesterol profile, basal metabolic rate (if possible), 
and bone density. Thyroidectomy is been reserved for 
individuals with pronounced hyperthyroid symptoms 
and compressive goitre, which cannot be controlled 
medically [20].
Patients with RTHb with symptoms of hyperthy-
roidism should be treated symptomatically. Adminis-
tration of b-blockers improves tachycardia and tremor. 
Treatment with dopaminergic drugs and somatostatin 
analogues, due to only transient benefits, have limited 
use. The thyroid hormone analogue triiodothyroacetic 
acid (TRIAC) is used in cases of individuals with PRTH 
with selective resistance accompanied by symptoms 
of hyperthyroidism. However, whether TRIAC has 
beneficial effects on all markers of TH action is not 
known [21].
Treatment of affected infants still remains contro-
versial. It is proposed that TH therapy (usually LT4) 
should be reserved for children with elevated serum 
TSH levels and developmental failure that cannot be 
explained by other illness or defect, or family history 
of growth or mental retardation [10]. Some authors 
have suggested short-term treatment with methima-
zole and iodine in hyperthyroid RTHb neonates [22]. 
Interestingly, liothyronine therapy may alleviate the 
symptoms of ADHD in a significant number of RTHb 
children [23]. In our patient, due to relatively mild 
symptoms, we decided against the use of anti-thyroid 
drugs and used beta-blockers to control tachycardia. 
Unfortunately, we had to discontinue therapy due to 
the side effects. The patient is now carefully followed by 
endocrinology and cardiology, and his thyroid function 
is regularly checked. 
Conclusion
We describe a case of RTHb caused by a common germ-
line mutation located at THRB exon 7 hot spot. In our 
study, both the patient and his mother had elevated 
FT3, FT4, and non-suppressed TSH concentration. 
They presented symptoms of hyperthyroidism, such 
as tachycardia, hyperactivity, and poor weight gain. It 
can be concluded that despite the rarity and atypical 
clinical presentation of the RTHb, primary care phy-
sicians, paediatricians, and endocrinologists should 
consider this diagnosis when evaluating individuals 
with hyperthyroxinaemia and non-suppressed TSH 
levels. The treatment should be individualised, but no 
therapy is fully effective.
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